Zoledronic acid
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-ZOLEDRONATE |
|---|---|
| Type | Drug |
| Aliases | ReclastZometaЗоледронова кислота |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-MM-2025 |
Drug Facts
| Class | Nitrogen-containing bisphosphonate |
|---|---|
| Mechanism | Binds hydroxyapatite in bone matrix; inhibits osteoclast farnesyl pyrophosphate synthase, disrupting the mevalonate pathway and inducing osteoclast apoptosis. Reduces skeletal-related events in myeloma bone disease. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Standard of care for myeloma-related bone disease — reduces skeletal- related events and pain. Calcium + vitamin D supplementation mandatory. Comprehensive dental evaluation BEFORE initiation; avoid invasive dental procedures during therapy. Monthly dosing for ≤2 years, then re-evaluate.
Used By
Supportive Care
SUP-BONE-HEALTH-PROSTATE- Prostate-cancer bone-health prophylaxisSUP-MM-BONE-PROTECTION- Multiple myeloma bone protection (bisphosphonate)